GSK plc
GSKNYSE
$51.76
↓ -1.9%Jul 17 close · end-of-day
Price
1Y↑ +40.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
No screener snapshot for this ticker.
Company profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital.
- CEO
- Emma N. Walmsley
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 90,100
- Website
- gsk.com
Earnings
No reported earnings periods on file.
Financial statements
No annual data.
No quarterly data.
Company news
Jul 17, 2026
- 3d agoSector Update: Healthcare Stocks Mixed Late Afternoonfinance.yahoo.com
- 3d agoGilead Leads The Battle Vs. HIV. But Rivals Are On The Move.finance.yahoo.com
- 3d agoEuropean Equities Traded in the US as American Depositary Receipts Decline Fridayfinance.yahoo.com
- 3d agoJefferies resumes GSK coverage at 'buy', sees 30% upside on oncology firepowerproactiveinvestors.com
- 3d agoGSK Discontinues Development of Camlipixant for Refractory Chronic Coughfinance.yahoo.com
- 3d agoExchange-Traded Funds, Equity Futures Lower Pre-Bell Friday as Investors Retreat From Chipmaker Stocksfinance.yahoo.com
Jul 13, 2026
Jul 9, 2026
- 11d agoConnective Tissue Disease Associated with Interstitial Lung Disease Market Report, Details Drug Class Breakdown Across Corticosteroids, Antifibrotics, Immunosuppressants, and Biologicsfinance.yahoo.com
- 11d agoSystemic Lupus Erythematosus Market at a Turning Point as 6 Late-Stage Emerging Therapies Set to Redefine Treatment Landscape | DelveInsightfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-12-11 | GLAXOSMITHKLINE PLC | Buy | 1,470,000 | $19.00 | $27.9M | filing |
Latest 1 transaction.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.